Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$4.01
-$0.28(-8.54%)
At close: 4:00 PM EST
$4.01
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$2.75 - $8.44
Previous CloseN/A
Volume1.71M
Average Volume (3M)6.59M
Market Cap
$1.62B
Enterprise Value$668.18
Total Cash (Recent Filing)$504.73M
Total Debt (Recent Filing)$140.18M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume5,102,016
30 Day Avg. Volume6,591,254
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.20Price Target Upside154.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$31.99M
Bulls Say, Bears Say
Bulls Say
Integrated Antibody Discovery PlatformAbCellera’s integrated discovery platform (high-throughput single-cell screening, microfluidics and functional assays) is a durable competitive asset. It enables repeatable, partner-funded discovery programs, shortens candidate selection timelines and supports diversified product opportunities across oncology and other therapeutic areas, sustaining deal flow and long-term service demand.
Robust Liquidity And Committed FundingA funded runway of roughly $655M including committed government support provides multi-year financing to advance internal clinical programs. This reduces near-term refinancing risk, allows sustained R&D investment, and gives management time to hit Phase II/IND milestones without immediate dependence on dilutive capital markets.
Clear Near-term Clinical CatalystsClearly scheduled clinical readouts (ABCL635 Phase II in Q3 2026, ABCL575 Phase I topline in Q4 2026) create repeatable de-risking events. Successful outcomes would validate target engagement, support downstream development/partnering, and materially advance internal pipeline positioning over the next 2–18 months.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business is not yet self-funding. Over the medium term this forces reliance on existing cash, milestone receipts, or new financing; it constrains strategic flexibility, can accelerate depletion of liquidity if clinical timelines slip, and raises funding execution risk.
Sustained Operating Losses And Negative ReturnsDeep, ongoing operating and net losses compress shareholder value and produce negative returns on equity. If losses persist while revenue remains modest, management must prioritize cost control or secure external capital, both of which can limit investment in growth or delay commercialization and long-term value capture.
Declining Partner Research-fee RevenueA strategic shift from partner-funded discovery toward internal programs reduces predictable service revenue. That structural change increases near-term revenue volatility and shifts value capture toward later milestones and royalties, delaying steady cash inflows and heightening reliance on successful clinical progression.
AbCellera Biologics News
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $2.75 and its highest was $8.44 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $1.62B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.031.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 305,375,400 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.20 (154.36% Upside)
$10.20 (154.36% Upside)
Blogger Sentiment
Neutral
ABCL Sentiment 50%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $95.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.76%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$10.20
▲(154.36% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
40.93% Insiders
4.67% Mutual Funds
0.27% Other Institutional Investors
52.42% Public Companies and Individual Investors